Gossamer Bio Sees Unusually High Options Volume (NASDAQ:GOSS)

Gossamer Bio, Inc. (NASDAQ:GOSS) saw unusually large options trading on Wednesday. Traders bought 32,685 put options on the stock. This represents an increase of 428% compared to the average daily volume of 6,189 put options.

Institutional Trading of Gossamer Bio

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Gossamer Bio by 5.2% in the third quarter. Vanguard Group Inc. now owns 12,009,773 shares of the company’s stock worth $31,586,000 after acquiring an additional 598,981 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Gossamer Bio by 12.4% during the 2nd quarter. Acadian Asset Management LLC now owns 7,146,022 shares of the company’s stock worth $8,786,000 after purchasing an additional 787,909 shares during the period. Geode Capital Management LLC grew its holdings in shares of Gossamer Bio by 100.4% during the 2nd quarter. Geode Capital Management LLC now owns 4,555,080 shares of the company’s stock worth $5,604,000 after purchasing an additional 2,282,632 shares during the period. Corient Private Wealth LLC increased its position in shares of Gossamer Bio by 8.9% during the 2nd quarter. Corient Private Wealth LLC now owns 3,693,683 shares of the company’s stock worth $4,543,000 after purchasing an additional 302,200 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in Gossamer Bio by 629.3% in the 3rd quarter. Millennium Management LLC now owns 3,619,329 shares of the company’s stock valued at $9,519,000 after buying an additional 3,123,081 shares during the period. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on GOSS shares. Barclays began coverage on Gossamer Bio in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $9.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Gossamer Bio in a report on Thursday, January 22nd. Wall Street Zen lowered shares of Gossamer Bio from a “hold” rating to a “sell” rating in a report on Friday, January 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Gossamer Bio in a research report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $8.60.

Gossamer Bio Stock Down 7.9%

NASDAQ GOSS opened at $2.46 on Thursday. The business’s fifty day simple moving average is $3.00 and its 200-day simple moving average is $2.65. The firm has a market cap of $569.39 million, a PE ratio of -3.57 and a beta of 1.93. Gossamer Bio has a 52 week low of $0.76 and a 52 week high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The firm had revenue of $13.29 million for the quarter, compared to analyst estimates of $6.32 million. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 354.50%. Research analysts expect that Gossamer Bio will post -0.28 EPS for the current year.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.